NASDAQ:ABUS Arbutus Biopharma Q2 2025 Earnings Report $3.13 -0.01 (-0.32%) Closing price 04:00 PM EasternExtended Trading$3.12 -0.01 (-0.32%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Arbutus Biopharma EPS ResultsActual EPSN/AConsensus EPS -$0.02Beat/MissN/AOne Year Ago EPSN/AArbutus Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArbutus Biopharma Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, July 31, 2025Conference Call Time8:45AM ETConference Call ResourcesEarnings HistoryCompany Profile Arbutus Biopharma Earnings HeadlinesArbutus Biopharma Corporation (ABUS) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comArbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical FocusJune 25, 2025 | globenewswire.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 18 at 2:00 AM | Brownstone Research (Ad)Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal ProgressMay 18, 2025 | msn.comArbutus Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comArbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025May 10, 2025 | msn.comSee More Arbutus Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email. Email Address About Arbutus BiopharmaArbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing curative therapies for patients with chronic hepatitis B virus (HBV) infection. Headquartered in Warminster, Pennsylvania, with research and development operations in Vancouver, Canada, Arbutus leverages its proprietary lipid nanoparticle (LNP) delivery platform and RNA interference (RNAi) programs to advance a pipeline of therapies designed to achieve functional cure of HBV. The company’s lead investigational product, AB-729, is an RNAi therapeutic that targets viral transcripts, aiming to reduce key viral proteins and restore immune control. Arbutus is also developing small-molecule capsid assembly modulators (AB-101 and AB-201) to inhibit viral replication by disrupting the formation of the hepatitis B virus capsid. These programs reflect Arbutus’s integrated approach, combining novel delivery technology with complementary antiviral mechanisms to address multiple stages of the HBV lifecycle. Since its formation in 2015 through the combination of Tekmira Pharmaceuticals and OnCore Biopharma, Arbutus has built a robust intellectual property portfolio covering LNP formulation and formulation components, RNAi chemistries and HBV-related patents. The company maintains strategic collaborations and licensing agreements to extend its platform capabilities and broaden its reach in antiviral development. Under the leadership of President and Chief Executive Officer Mark J. F. Myers, Arbutus Biopharma is committed to advancing global efforts against chronic hepatitis B. With a presence in North America and partnerships across Europe and Asia, the company seeks to deliver innovative therapies that could transform the treatment landscape and improve outcomes for millions of patients worldwide.Written by Jeffrey Neal JohnsonView Arbutus Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
